Vigil Neuroscience is a company that discovers therapeutics for neurodegenerative diseases. It focuses on microglia and develops VGL101, a fully human monoclonal antibody targeting human TREM2 for the treatment of rare microgliopathies. The company also specializes in the small molecule program, an orally-available, small molecule TREM2 agonist for the treatment of more common neurodegenerative diseases